text:
Power restored for many in west Columbia
COLUMBIA —As of 3 p.m., power remains out for 347 Columbia customers, according to the City of Columbia's outage map.
At least 1,200 customers were without power in west Columbia earlier Tuesday.
The Boone County Joint Communications office has tweeted that the outage has impacted traffic signals. The traffic signal is out at Scott Boulevard and Rollins.
More News
COLUMBIA- Volunteers worked to make 50,000 renewal kits for students, faculty, and staff. The kit is designed to curb... More >>
JEFFERSON CITY — JC Schools held a virtual session, Friday, to answer questions from parents and staff regarding the fall... More >>
COLUMBIA – The Boone County Commission released a letter on Friday, defending decisions made concerning CARES Act funding. On... More >>
JEFFERSON CITY - Some ballots requested near the state's deadline may not be returned by mail in time to be... More >>
COLUMBIA — This school year, some parents are responsible for juggling jobs and helping teach their children outside the... More >>
KANSAS CITY (AP) — Police have identified a man who was found shot to death in a grassy lot in... More >>
(CNN) -- Police have charged a 25-year-old man with first-degree murder after they say he shot and killed a 5-year-old... More >>
COLUMBIA — Missouri prosecutors on Wednesday came out against Republican Gov. Mike Parson's proposal to give the state attorney... More >>
WASHINGTON (AP) — President Donald Trump is making clear why he opposes extra money for the cash-strapped U.S. Postal Service.... More >>
( Missourian ) - Want to support Columbia businesses that are struggling through the pandemic and not leave your... More >>
SPRINGFIELD (AP) — Police in southwestern Missouri are investigating the shooting death of a man in Springfield. Police said... More >>
ST. LOUIS — The newest Major League Soccer team will be called St. Louis City SC when it debuts... More >>
Friday COVID-19 Coverage: Two people moving into State Fair Community College residence hall test positive
As COVID-19 continues to spread, KOMU 8 will continue to update you about impacts in the community. You can... More >>
(CNN) -- Boris Johnson's latest strategy to fight coronavirus aims to make Britain healthier -- but campaigners are worried about... More >>
KANSAS CITY, Mo. (AP) — A man has been charged in the shooting death of a 4-year-old Kansas City, Missouri,... More >>
COLUMBIA - Forum Boulevard closed throughout the night for construction workers to build storm sewer drainage between Green Meadows Road... More >>
COLUMBIA - Columbia's City Council discussed homelessness Thursday during their budget work session. Ward 1 Council Member, Pat Fowler,... More >>
(AP) - The NCAA will not conduct fall championship events - a move that does not effect major college football... More >>


text:
Rush, Grateful Patient of Dr. Lisa Shnayder
My story begins like many other people's stories concerning cancer. I went to my family doctor for a routine exam in mid-January of this year. Being a Type II diabetic, my personal physician insisted that I come in every three months to monitor the progress of the medication controlling my disease. During the poking and prodding of the examination, he asked if I knew I had a swollen lymph node in my neck. My immediate reaction was a puzzled sounding, "What?"
The doctor put me on a course of antibiotics to see if the swelling of the lymph nodes would go away. After two weeks, there was no change. The node was swollen, hard and not showing any sign of pain. It was decided that a CT scan was in order to see what was there. The scan revealed a swollen lymph node pressing against the windpipe and a trip to an ENT was scheduled. This visit led to a needle biopsy to determine what was causing my lymph node swell. The results showed that I had a squamous cell cancer. My ENT immediately recommended me Dr. Lisa Shnayder at KU Med. She told me the Dr. Shnayder was an ENT who specialized in this field and was the person I needed to see.
It seems like a whirlwind now. I got to meet Dr. Shnayder and was immediately taken by her positive outlook, her professionalism and the obvious expertise she had in the field. She immediately gained my trust and I literally placed my life in her hands. That turned out to be the most important decision I've ever made in my life.
Dr. Shnayder performed the biopsy that determined the primary site of my cancer on the base-of-tongue. She followed that up with surgery to remove the primary cancer and the infected lymph nodes in my neck. She helped guide me through process of treatment for head and neck cancer - and it was done by using state-of-the-art technologies and the latest cutting edge knowledge afforded by a research institution like the University of Kansas Medical Center. I'm now about six months post treatment for cancer. I see Dr. Shnayder every few months to monitor my progress and my latest scans showed that I was clean thus far.
Thanks to Dr. Shnayder's recommendations and expert advice I have a few other items to report. I began this journey with a number of health concerns. I was a Type II diabetic and took two medications to control it. I had high blood pressure and took medication to control that. I had high cholesterol and triglycerides and took two separate medications to control that. I was overweight, didn't exercise enough, didn't eat right, used tobacco on occasion and drank alcohol more than I should have.
I've now lost 100 pounds since this process began. I eat right. I exercise regularly. I don't use tobacco or alcohol. I no longer take medications for Type II diabetes or for high blood pressure. I take a single, low dose medication for cholesterol. That is precautionary as even my cholesterol is on the low side of borderline unhealthy. Thank you Dr. Shnayder! You're the best!

subset: commoncrawl


text:
Previous Chapter | Table of Contents | Next Chapter
We Still Must Chase Your Mother
Ru Jia was practically scared silly, as she reflexively turned to run. Unfortunately, in this sort of time, how could she still manage to run? Feng Yu Heng's small hand was placed on her shoulder. Seemingly without using any force, Ru Jia was picked up. In a flurry, she was tossed into the room.
The door of the shop was closed up once more. Ru Jia raised her head and happened to be facing Xuan Tian Ming's golden mask. In this dim light, the mask still reflected light, blinding her and causing her eyes to hurt.
Ru Jia turned her head away and found that there were four clerks on the floor of the shop. They had been tied up and tossed into a corner. They could not move, and they could not speak. It looked as though their eyes were filled with despair and desperation.
Just like how she hoped that the people in the shop could save her life, the people in the shop from Qian Zhou hoped that the two princesses could save their lives. Unfortunately, since her hopes had come up empty, the only path left for them was death.
Xuan Tian Ming looked up and said to Bai Ze: "Take them all to the back and interrogate them. Get the exact locations of their other hiding spots from them."
Bai Ze smile and walked over to Ru Jia. Reaching out, he grabbed her arm and dragged her over to the corner. When they arrived in front of the four clerks, he finally said: "Let's go! Follow this one out back to speak clearly."
Roughly one hour later, Bai Ze finally returned to the room. Saluting the two, he said: "One of the clerks was unable to handle the torture and revealed everything. There are another three gathering points in the capital. They are in the North, West and East parts of the city. This subordinate remembers their locations."
"Good." Xuan Tian Ming stood up and curled his lips into a sneer. He then reached out to Feng Yu Heng, "Beloved consort, this prince will bring you to fight!"
In this sort of night with violent lightning storm and strong winds, the ninth prince, Xuan Tian Ming, and county princess Ji An, Feng Yu Heng, braved the lightning and rain, going to the four locations. One was a steamed bun shop, one was a pastry shop, one was a jewelry shop, and one was a rice shop, and they were all destroyed by the two. All of the people inside were captured, with none dying. All were captured alive.
The soldiers that had gone with them to take care of things were completely dazed. They had never seen things handled in such a swift manner, and they had never seen this sort of swift fighting style. They had heard rumors that the ninth prince was an expert martial artist, and they had heard that county princess Ji An was a divine doctor. But it was only today that they knew that their martial arts abilities were truly amazing. It was as though they were envoys from hell, here to collect lives. With an aura of murderous intent, they claimed the lives that they had come for on this stormy night.
This heavy downpour made their actions even more covert. The citizens kept their doors and windows firmly shut to hide from the wind and rain. Even if there was some movement outside, they would be completely covered up by the rumbling of thunder. Nobody knew what had happened that night. Only after the rain and wind stopped the next morning and everyone went out to buy steamed buns and pastries did everyone find that the shops had changed management.
But nobody cared if it had changed or not. They had managed to buy what they wanted to eat. Everything else was irrelevant.
When the hidden agents from the four shops and Ru Jia were sent to the prison in the mountain, Kang Yi, who had been enduring the entire time without speaking out finally let out a shriek and burst into tears. As for Feng Kun, he finally understood that Qian Zhou could not defeat Da Shun. In just a short night, the preparations that they had made over ten years was all wasted.
At this time, Xuan Tian Ming and Feng Yu Heng were already standing in Zhao He Hall's bedroom. They had just finished telling the Emperor, who was putting on his dragon robe and getting ready for the morning court session, about everything that had happened the previous night.
The Emperor was quite hotblooded while listening, as he interjected many times, repeatedly exclaiming good. This caused Zhang Yuan to feel very helpless, and he had to remind him: "Your Majesty, you've already spent an hour putting on that dragon robe. Can you allow this servant to properly help you finish putting it on?"
How could the Emperor still be worried about putting on clothes. He simply removed the robe that he could not tie properly no matter what then put his hands behind his back and walked around the room a few times. When he finally stopped, he had a solemn look on his face.
"We can practically hear the sound of weapons clashing on the battlefield between Qian Zhou and Da Shun. A few years ago, the Northern border would occasionally have some criminals wandering around, but Da Shun's attitude was mainly to appease them. This time, they completely tore away at our face. Since they wish to fight, we must get ready! Only now, we must focus on producing steel." He looked at Feng Yu Heng, "Half a year is too long. We can only give you three months. After three months, there needs to be at least enough weapons for the soldiers of the military camp in the suburbs of the capital."
Feng Yu Heng pulled her eyebrows together. Three months was too rushed. However, she also knew about the strong relations. The matter of Qian Zhou could no longer be dragged out for another three months. As long as this news made it to Qian Zhou, that side would definitely take action. The three northernmost provinces would be the first to be affected. For Da Shun, this was too great of a danger.
She pondered for a long time then nodded, "I will do my best."
The Emperor, however, corrected her: "It's not do your best. You must succeed."
Xuan Tian Ming became unhappy, "What is this about must? Is steel something that can be made just by talking about it?"
Feng Yu Heng tugged at his sleeve and shook her head, "We do need to work hard. No matter how we look at it, there is not enough time."
Xuan Tian Ming naturally understood this logic. He just could not get used to seeing the Emperor press Feng Yu Heng. After thinking a little, he added: "Aside from steel, we at least have a new Divine Intent Army. That is also important."
"Right." Feng Yu Heng said: "The Divine Intent Army will indeed be able to buy us a bit of time. We will deploy them as quickly as possible. Right now, we will secretly deploy a small group from the support team to the Northern border. We'll see if we can deploy any small but useful arrays."
The Emperor waved his hand: "We do not care what methods you use!" He said this while sitting in his chair. He then said to Xuan Tian Ming: "You also saw it. Your old man's body is deteriorating with each passing day. That's why this matter with Qian Zhou, from a filial perspective, is something that you should not trouble Us with. Moreover, this is so you can provide the world to your wife. As long as Qian Zhou is defeated, she will become the queen of Qian Zhou."
Xuan Tian Ming heard this, "Do you want to just leave this matter to someone else?"
The Emperor glared at him: "What is there to care about? Didn't you already say it? We are old, and my body is unwell. Even if I wanted to handle it, I do not have the energy to. Also, sooner or later, you would need to take care of this. Just treat this as practice." Pausing a little, he added with some worry: "If someone else wanted this chance to practice, they would not get it, tsk!"
Xuan Tian Ming's nose nearly became crooked from the anger. This old man had this sort of temper. No matter how serious the matter at hand, he would use very improper methods.
The Emperor gave him a great deal of face. To say that he was using improper methods, he used even more improper methods. "Also, don't We still need to go chase after your mother? Between your mother and the court, are you unable to tell which one is more important?"
Xuan Tian Ming rolled his eyes, "Your meaning is that imperial concubine mother is more important than Da Shun."
The Emperor opened his mouth, and it looked like he was about to say yes, but, in the end, after receiving a glare from Zhang Yuan, he did not speak the extremely improper words. He could only say: "Doesn't Da Shun still have you!"
Feng Yu Heng knew that this discussion between father and son would never end and quickly interjected, picking something for the Emperor to promise: "After defeating Qian Zhou, it will really belong to me?"
The Emperor nodded, "Of course."
"Good." She also became happy, "At first, I wanted Qian Zhou for the Tianshan snow lotuses, but I was busy while in seclusion. I heard that they ended up drying out. After obtaining Qian Zhou, that will no longer be a rare item. I will need to come back to Da Shun to open a hospital. Father Emperor, you have said it, when I open a hospital, you will have a share."
Either way, the Emperor was unable to understand what this so-called hospital was and thought that it might be something like Hundred Herb Hall. At the worst, he would just open a few more. How much money was there in having a share? He simply said: "When the time comes, We will give you some money. There is no need for a share."
Feng Yu Heng nodded, "Then it has been settled."
Xuan Tian Ming, however, saw a cunning look in her eyes and knew that the old man was about to be scammed!
Feng Yu Heng still had another matter, saying to the Emperor: "I must send my mother to Xiao Zhou immediately. Father Emperor, do not worry. After returning from Xiao Zhou, I will return immediately to the military camp."
The Emperor rambled a little more. Zhang Yuan hurried him a few times to get to court before he finally began putting on his outer robe once more.
Right before leaving, he did not forget to remind Xuan Tian Ming: "Don't forget, the matter of the battles will be left to you two to handle!"
Xuan Tian Ming pulled Feng Yu Heng along, practically running away from the imperial palace.
"That old man is becoming more and more improper." He muttered inside the imperial carriage; however, Feng Yu Heng heard this.
She said: "In truth, father Emperor is hoping to pass along the throne to you, right? He has already made it this clear. You should understand what he means. Before, he made an issue of your injury to make sure the opposition would turn their attention elsewhere, giving you a great deal of safety. Now, he wants to use the remainder of his life helping you become a good emperor as soon as possible. Father Emperor is well-intentioned. Whether it is from a ruler-subject perspective or a father-son perspective, he should receive a perfect score."
Xuan Tian Ming sighed and grabbed her hand, "I know, but I don't want him to accept his old age and declining health. That's all."
Feng Yu Heng no longer spoke. She knew that the father and son had a deep relationship. Otherwise, it would have been impossible for the Emperor to dote on this son to this degree.
The imperial carriage went all the way to the Feng manor's entrance when Feng Yu Heng called for it to stop. Xuan Tian Ming asked her: "Returning to the Feng manor?"
She nodded, "After leaving the capital for many months, I should go back to give a greeting. Also, we must find a way to delay the matter with Qian Zhou. I was thinking of going to see if there was anything that Kang Yi had written. We can copy her writing and send a letter back to Qian Zhou, reporting her safety."
Xuan Tian Ming thought a little then said: "This is also fine. Just be careful. You did not sleep for an entire night. You must rest first. There is no rush on the letter."
"Okay." She smiled and got out of the carriage then looked up and said: "If you have a chance, remember to come and see me." She then lifted the hem of her dress and ran into the manor.
Xuan Tian Ming looked at her small appearance and felt that it was funny. He thought to himself that when his wife was fierce, she was like a poisonous scorpion. When she looked innocent, she still looked like a 13-year-old little girl.
The people of the Feng manor had not seen Feng Yu Heng in many months. Now that she suddenly entered the manor, it gave everyone a fright. After being stunned for a moment, they finally managed to react and quickly go forward to salute: "This servant greets second young miss. Second young miss, you've returned!"
Feng Yu Heng greeted them while walking into the manor. She felt that the atmosphere in the manor was very oppressive, and there was not a single movement. Thinking about it, it must be that nobody slept last night, and they were all catching up on sleep now. She thought a little and turned toward Tian Xiang courtyard. At this time, she heard the sound of rushed footsteps coming from behind.


text:
Figure. Observed vs estimated depression severity time trends for drug vs placebo in 37 adult and geriatric studies. HAM-D indicates Hamilton Depression Scale.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits From Antidepressants: Synthesis of 6-Week Patient-Level Outcomes From Double-blind Placebo-Controlled Randomized Trials of Fluoxetine and Venlafaxine. Arch Gen Psychiatry. 2012;69(6):572–579. doi:10.1001/archgenpsychiatry.2011.2044
© 2020
Author Affiliations: Departments of Medicine, Health Studies, and Psychiatry (Dr Gibbons) and Center for Health Statistics (Dr Gibbons, Hur, and Brown), University of Chicago, and Department of Psychiatry, University of Illinois at Chicago (Dr Davis), Chicago, and Center for Medication Safety, Pharmacy Benefit Management Services, Hines Veterans Affairs Hospital, Hines (Dr Hur); Prevention Science and Methodology Group, Center for Family Studies, Department of Epidemiology and Public Health, University of Miami, Miami, Florida (Dr Brown); and Department of Molecular Imaging and Neuropathology, New York State Psychiatric Institute and Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York (Dr Mann).
Context Some meta-analyses suggest that efficacy of antidepressants for major depression is overstated and limited to severe depression.
Objective To determine the short-term efficacy of antidepressants for treating major depressive disorder in youth, adult, and geriatric populations.
Data Sources Reanalysis of all intent-to-treat person-level longitudinal data during the first 6 weeks of treatment of major depressive disorder from 12 adult, 4 geriatric, and 4 youth randomized controlled trials of fluoxetine hydrochloride and 21 adult trials of venlafaxine hydrochloride.
Study Selection All sponsor-conducted randomized controlled trials of fluoxetine and venlafaxine.
Data Extraction Children's Depression Rating Scale–Revised scores (youth population), Hamilton Depression Rating Scale scores (adult and geriatric populations), and estimated response and remission rates at 6 weeks were analyzed for 2635 adults, 960 geriatric patients, and 708 youths receiving fluoxetine and for 2421 adults receiving immediate-release venlafaxine and 2461 adults receiving extended-release venlafaxine.
Data Synthesis Patients in all age and drug groups had significantly greater improvement relative to control patients receiving placebo. The differential rate of improvement was largest for adults receiving fluoxetine (34.6% greater than those receiving placebo). Youths had the largest treated vs control difference in response rates (24.1%) and remission rates (30.1%), with adult differences generally in the 15.6% (remission) to 21.4% (response) range. Geriatric patients had the smallest drug-placebo differences, an 18.5% greater rate of improvement, 9.9% for response and 6.5% for remission. Immediate-release venlafaxine produced larger effects than extended-release venlafaxine. Baseline severity could not be shown to affect symptom reduction.
Conclusions To our knowledge, this is the first research synthesis in this area to use complete longitudinal person-level data from a large set of published and unpublished studies. The results do not support previous findings that antidepressants show little benefit except for severe depression. The antidepressants fluoxetine and venlafaxine are efficacious for major depressive disorder in all age groups, although more so in youths and adults compared with geriatric patients. Baseline severity was not significantly related to degree of treatment advantage over placebo.
Recent reports suggest that the efficacy of antidepressant medications compared with placebo may be overstated owing to publication bias1 and that antidepressants have less efficacy for mildly depressed patients.2,3 For example,1 of 74 US Food and Drug Administration–registered randomized controlled trials (RCTs) involving 12 antidepressants in 12 564 patients, 94% of published trials were positive, whereas only 51% of all US Food and Drug Administration–registered studies were positive. A meta-analysis2 of 35 RCTs of 4 antidepressants (fluoxetine hydrochloride, venlafaxine hydrochloride, nefazodone hydrochloride, and paroxetine hydrochloride) found that only studies with higher average baseline severity achieved the putative clinically significant 3-point difference in Hamilton Depression Scale (HAM-D) scores.4 A study3 of individual-level data from 6 RCTs comparing paroxetine or imipramine hydrochloride with placebo concluded that there was benefit only for those with very severe depression.
Questions regarding these studies have been raised.5 First, the RCT data may not generalize to patients in the real world, who could be switched to another medication if unresponsive. The National Institute of Mental Health–funded STAR*D trial found a 67% remission rate for patients who finished all 4 phases of the trial. Second, a recent meta-analysis6 of new-generation antidepressants (7334 patients in 56 RCTs) failed to detect an association between the trial's average baseline severity and treatment response. Third, there is a lack of clinically informative outcomes such as the percentage of patients experiencing response or remission.
We question the meaning of a relationship between average study-level initial severity and treatment response.7 Patient-level data are required to draw this type of inference as conducted by Fournier et al.3 We also question the use of so-called vote-counting methods used by Turner et al1 where a simple tally of positive studies is used to draw an inference to overall efficacy of a treatment. Our work extends beyond that of Fournier et al3 by including a much larger number of trials, accounting for heterogeneity in growth curves within and across studies, and better handling dropouts.8-10
We obtained complete longitudinal patient records for RCTs of fluoxetine (a widely used selective serotonin reuptake inhibitor) conducted by Eli Lilly and Co, the Treatment for Adolescents With Depression Study of fluoxetine in youths by the National Institute of Mental Health, and adult studies for venlafaxine (a widely used serotonin-norepinephrine reuptake inhibitor) conducted by Wyeth. These patient-level data allow us to do the following: (1) examine associations between treatment response and baseline severity measured at the patient level; (2) use all available longitudinal data from each subject; (3) fit models with less restrictive assumptions regarding missing data; and (4) minimize the effects of selection or publication bias by including nearly all of the placebo-controlled depression RCTs of fluoxetine and venlafaxine.
All trials were double-blind, placebo-controlled RCTs. For fluoxetine, we reanalyzed studies that included 30 or more patients and used the HAM-D for adults and geriatric patients or the Children's Depression Rating Scale–Revised (CDRS-R) for youths. The only trial exclusions were 1 adult study that did not use the HAM-D, 1 study judged to be invalid, and 1 youth study that did not use the CDRS-R. Fluoxetine trial data from the Treatment for Adolescents With Depression Study11 were obtained from the National Institute of Mental Health; individual-level data for the remaining 12 adult studies, 4 geriatric studies, and 3 youth studies were obtained from Eli Lilly and Co. We obtained patient-level data from Wyeth for all available adult venlafaxine RCTs (11 with venlafaxine immediate release [IR] and 10 with venlafaxine extended release [ER]).
For fluoxetine, we analyzed data from 12 adult studies with 2635 patients and 14 048 measurements; 4 geriatric studies with 960 patients and 5209 measurements; and 4 youth studies with 708 patients and 2536 measurements. For the adult trials, 11 were outpatient and 1 had both inpatient and outpatient settings. Inclusion required a diagnosis of depression closely resembling major depressive disorder (MDD), and the modal trial dosage was 20 mg/d of fluoxetine hydrochloride (range, 20-80 mg/d). The geriatric trials included 3 outpatient trials and 1 inpatient trial; all subjects had depression (similar to MDD) and were older than 60 years. The modal trial dosage was 20 mg/d (range, 10-30 mg/d). The youth data consisted of 3 outpatient trials and 1 inpatient trial; all subjects had depression (similar to MDD) and were aged 7 to 18 years. The modal trial dosage was 20 mg/d (range, 10-40 mg/d).
The Treatment for Adolescents With Depression Study was a 2 × 2 factorial design of fluoxetine and cognitive behavior therapy for the treatment of MDD in adolescents. The study involved 439 patients aged 12 to 17 years randomly assigned to the 4 treatment conditions. Our analysis included only placebo and fluoxetine arms. Study dosages were 10 to 40 mg/d. Dosages of placebo and fluoxetine hydrochloride began at 10 mg/d; the dosages were then increased to 20 mg/d at week 1 and, if necessary, to a maximum of 40 mg/d by week 8. Modal dosages were not available for the venlafaxine trials; however, ranges are reported in the Table.
For venlafaxine IR, there were 11 adult studies with 2421 patients and 10 634 measurements; for venlafaxine ER, there were 10 adult studies with 2461 patients and 12 481 measurements. The majority of the studies were outpatient (venlafaxine IR, 2 inpatient and 9 outpatient; venlafaxine ER, 10 outpatient). Dosages were in the range of 25 to 375 mg/d (modal range, 75-150 mg/d). The Table provides a summary of the trials.
Analyses were conducted using SuperMix software.12 Data were analyzed using a 3-level mixed-effects linear regression model.10 Level 1 represents the measurement occasion; level 2, the patient; and level 3, the study. An overall analysis was performed for both drugs (fluoxetine and venlafaxine IR and ER) in adults and geriatric patients. Youths were not included in the combined analysis because they were assessed with the CDRS-R. Separate analyses were performed for fluoxetine adult, geriatric, and youth trials and venlafaxine IR and ER adult trials. The intercept and slope of the time trends were random effects at both patient and study levels, allowing time trends to vary across patients and studies. Heterogeneity of the treatment effect was tested by including a random treatment × time interaction. Time was the number of days from treatment initiation. The primary effect of interest was the change in slope between treatment and control over 6 weeks. Six weeks was selected because it was the minimum trial duration and therefore we were able to perform an analysis in which study and length of treatment were unconfounded. We report the marginal maximum likelihood estimate (MMLE) and standard error of the difference in HAM-D or CDRS-R scores at 6 weeks between treated and control groups. As a sensitivity analysis, we analyzed scheduled weekly visit data (ie, intended week of the visit instead of the actual day of the visit). We evaluated models with nonlinear time trends; however, the linear model provided the best overall fit to the data through 6 weeks. To test for the treatment effect's dependence on initial severity, we dichotomized baseline severity (HAM-D score13 >20; CDRS-R score14 >60) at the subject level and included interactions with treatment and time effects, with the estimate of interest being the 3-way severity × treatment × time interaction. The data were also analyzed using a continuous baseline severity score. These analyses included all 2- and 3-way interactions to determine whether baseline severity moderated the relationship between treatment and response. All analyses were adjusted for main effects of age and sex, which decreases variability but does not determine whether age and sex are treatment moderators. Age-specific analyses (youth, adult, geriatric) address the question of differential treatment effects across the lifespan.
Empirical Bayes estimates were used to estimate response and remission at the end of 6 weeks for each patient and were compared using a mixed-effects logistic regression model adjusting for study. As a sensitivity analysis, the observed baseline and week 6 HAM-D or CDRS-R scores were used if available. Among all subjects, 52.2% had a score during week 6 and 21.4% had a score on day 42. The observed day 42 scores were used in the sensitivity analysis. For adults and geriatric patients, response was a 50% reduction in the HAM-D score at week 6 and remission was a HAM-D score lower than 8. For youths, response was a 50% reduction in the CDRS-R score at week 6 and remission was a CDRS-R score lower than 28. The number needed to treat (NNT) to obtain a single additional remission or response in the treatment arm relative to the placebo arm was also reported.
The estimated average rates of change over 6 weeks were −11.82 HAM-D units for drug vs −9.26 HAM-D units for placebo (MMLE = −2.55; SE = 0.20; P < .001), indicating 27.7% greater improvement for drug. Analyses based on weekly data yielded virtually identical results. Estimated linear time trends and observed daily mean scores are presented in the Figure. Variation in the treatment effect over studies was not statistically significant (SD = 0.16; P = .06).
The estimated response rates were 58.4% for drug vs 39.9% for placebo (odds ratio [OR] = 2.11; 95% CI, 1.93-2.31; P < .001; NNT = 5.41). Similar results were obtained using available observed HAM-D scores (59.1% for drug vs 41.9% for placebo; OR = 2.00; 95% CI, 1.83-2.19; P < .001; NNT = 5.82). Remission rates were 43.0% vs 29.3% for drug and placebo, respectively (OR = 1.82; 95% CI, 1.66-2.00; P < .001; NNT = 7.30), and the sensitivity analysis revealed similar results (42.4% for drug vs 28.9% for placebo; OR = 1.81; 95% CI, 1.65-1.99; P < .001; NNT = 7.39).
No effect of baseline severity on treatment efficacy was found for either the dichotomous (P = .27) or continuous (P = .10) baseline severity measures. For patients with low severity, the rates of change in symptoms over 6 weeks were −9.40 HAM-D units for drug vs −7.20 HAM-D units for placebo. For patients with high severity, the rates of change were −12.85 for drug vs −10.07 for placebo. The estimated differences were 2.20 HAM-D units (95% CI, 1.65-2.76) for low severity and 2.78 HAM-D units (95% CI, 2.26-3.29) for high severity. Estimated response rates for treated vs placebo-receiving patients were 54.8% vs 37.3% (difference of 17.5%), respectively, for low severity and 57.7% vs 40.5% (difference of 17.2%), respectively, for high severity. Estimated remission rates for treated vs placebo-receiving patients were 49.9% vs 36.6% (difference of 13.3%), respectively, for low severity and 37.8% vs 25.1% (difference of 12.7%), respectively, for high severity.
In adult studies of fluoxetine, the estimated average rates of change over 6 weeks were −10.12 HAM-D units for fluoxetine and 7.52 HAM-D units for placebo (MMLE = −2.60; SE = 0.34; P < .001), indicating 34.6% greater improvement for fluoxetine.
The estimated response rates were 55.1% for fluoxetine vs 33.7% for placebo (OR = 2.41; 95% CI, 1.93-3.01; P < .001; NNT = 4.69). Remission rates were 45.8% vs 30.2% for fluoxetine and placebo, respectively (OR = 1.96; 95% CI, 1.66-2.31; P < .001; NNT = 6.40).
No effect of baseline severity on treatment efficacy was found (P = .14). For patients with low severity, the rates of change in symptoms over 6 weeks were −7.98 HAM-D units for fluoxetine vs −6.26 HAM-D units for placebo. For patients with high severity, the rates of change were −11.72 HAM-D units for fluoxetine vs −8.32 HAM-D units for placebo. The estimated differences were 1.68 HAM-D units (95% CI, 0.77-2.59) for low severity and 3.40 HAM-D units (95% CI, 2.49-4.31) for high severity. Estimated response rates for treated vs placebo-receiving patients were 50.0% vs 36.4% (difference of 13.6%), respectively, for low severity and 56.2% vs 32.7% (difference of 23.5%), respectively, for high severity. Estimated remission rates for treated vs placebo-receiving patients were 51.7% vs 41.2% (difference of 10.5%), respectively, for low severity and 37.8% vs 22.1% (difference of 15.7%), respectively, for high severity. Neither response rates nor rates of improvement differed statistically between low- and high-severity groups.
In adult studies of venlafaxine ER, the estimated average rates of change over 6 weeks were −12.39 HAM-D units for venlafaxine ER and −10.21 HAM-D units for placebo (MMLE = −2.18; SE = 0.38; P < .001), indicating 21.4% greater improvement for venlafaxine ER.
The estimated response rates were 60.5% for venlafaxine ER vs 45.4% for placebo (OR = 1.92; 95% CI, 1.61-2.29; P < .001; NNT = 6.63). Remission rates were 41.5% vs 29.5% for venlafaxine ER and placebo, respectively (OR = 1.75; 95% CI, 1.46-2.09; P < .001; NNT = 8.31).
No effect of baseline severity on treatment efficacy was found (P = .94). For patients with low severity, the rates of change were −9.58 HAM-D units for venlafaxine ER vs −7.10 HAM-D units for placebo. For patients with high severity, the rates of change were −12.81 HAM-D units for venlafaxine ER vs −10.58 HAM-D units for placebo. The estimated differences were 2.48 HAM-D units (95% CI, 0.91-4.05) for low severity and 2.23 HAM-D units (95% CI, 1.40-3.05) for high severity. Estimated response rates for treated vs placebo-receiving patients were 53.1% vs 36.6% (difference of 16.5%), respectively, for low severity and 59.9% vs 45.5% (difference of 14.4%), respectively, for high severity. Estimated remission rates for treated vs placebo-receiving patients were 52.1% vs 35.2% (difference of 16.9%), respectively, for low severity and 40.0% vs 28.6% (difference of 11.4%), respectively, for high severity.
In adult studies of venlafaxine IR, the rates of change over 6 weeks were −14.32 HAM-D units for venlafaxine IR and −10.71 HAM-D units for placebo (MMLE = −3.61; SE = 0.42; P < .001), indicating 33.7% greater improvement for venlafaxine IR.
The estimated response rates were 67.2% for venlafaxine IR vs 45.2% for placebo (OR = 3.16; 95% CI, 2.52-3.97; P < .001; NNT = 4.53). Remission rates were 47.1% vs 32.4% for venlafaxine IR and placebo, respectively (OR = 2.24; 95% CI, 1.82-2.75; P < .001; NNT = 6.83).
No effect of baseline severity on treatment efficacy was found (P = .29). For patients with low severity, the rates of change were −10.08 HAM-D units for venlafaxine IR vs −7.69 HAM-D units for placebo. For patients with high severity, the rates of change were −14.87 HAM-D units for venlafaxine IR vs −10.88 HAM-D units for placebo. The estimated differences were 2.39 HAM-D units (95% CI, 0.33-4.46) for low severity and 3.99 HAM-D units (95% CI, 3.08-4.90) for high severity. Estimated response rates for treated vs placebo-receiving patients were 64.7% vs 43.9% (difference of 20.8%), respectively, for low severity and 66.5% vs 43.0% (difference of 23.5%), respectively, for high severity. Estimated remission rates for treated vs placebo-receiving patients were 57.0% vs 43.3% (difference of 13.7%), respectively, for low severity and 45.3% vs 29.4% (difference of 15.9%), respectively, for high severity.
In geriatric studies of fluoxetine, the estimated average rates of change over 6 weeks were −7.48 HAM-D units for placebo and −8.86 HAM-D units for fluoxetine (MMLE = −1.39; SE = 0.50; P = .009), indicating 18.5% greater improvement for fluoxetine. However, response and remission rates were not significantly different between treated and control conditions.
The estimated response rates were 37.3% for fluoxetine vs 27.4% for placebo (OR = 1.42; 95% CI, 0.92-2.18; P = .12; NNT = 16.95). Remission rates were 26.5% vs 20.0% for fluoxetine and placebo, respectively (OR = 1.26; 95% CI, 0.78-2.03; P = .34; NNT = 38.71).
No effect of baseline severity on treatment efficacy was found (P = .95). For patients with low severity, the rates of change were −6.89 HAM-D units for fluoxetine vs −5.42 HAM-D units for placebo. For patients with high severity, the rates of change were −9.37 HAM-D units for fluoxetine vs −8.02 HAM-D units for placebo. The estimated differences were 1.47 HAM-D units (95% CI, −0.26 to 3.20) for low severity and 1.34 HAM-D units (95% CI, 0.02 to 2.67) for high severity. Estimated response rates for treated vs placebo-receiving patients were 38.1% vs 26.9% (difference of 11.2%), respectively, for low severity and 37.1% vs 26.5% (difference of 10.6%), respectively, for high severity. Estimated remission rates for treated vs placebo-receiving patients were 38.1% vs 27.6% (difference of 10.5%), respectively, for low severity and 22.3% vs 16.4% (difference of 5.9%), respectively, for high severity.
In youth studies of fluoxetine, the estimated average rates of change over 6 weeks were −15.96 CDRS-R units for placebo and −20.58 CDRS-R units for fluoxetine (MMLE = −4.62; SE = 1.26; P < .001), indicating 29.0% greater improvement for fluoxetine.
The estimated response rates were 29.8% for fluoxetine vs 5.7% for placebo (OR = 6.66; 95% CI, 3.07-14.48; P < .001; NNT = 4.16). Remission rates were 46.6% vs 16.5% for fluoxetine and placebo, respectively (OR = 4.23; 95% CI, 2.64-6.77; P < .001; NNT = 3.33). The finding of higher remission rates than response rates questions the validity of the CDRS-R remission threshold score of 28.
No effect of baseline severity on treatment efficacy was found (P = .90). For patients with low severity, the rates of change in symptoms were −17.60 CDRS-R units for fluoxetine vs −12.56 CDRS-R units for placebo. For patients with high severity, the rates of change were −28.86 CDRS-R units for fluoxetine vs −24.40 CDRS-R units for placebo. The estimated differences were 5.04 CDRS-R units (95% CI, 2.56 to 7.52) for low severity and 4.45 CDRS-R units (95% CI, −0.58 to 9.49) for high severity. Estimated response rates for treated vs placebo-receiving patients were 23.0% vs 3.2% (difference of 19.8%), respectively, for low severity and 40.2% vs 17.2% (difference of 23.0%), respectively, for high severity. Estimated remission rates for treated vs placebo-receiving patients were 54.1% vs 19.4% (difference of 34.7%), respectively, for low severity and 28.9% vs 7.5% (difference of 21.4%), respectively, for high severity.
We examined symptom trajectories through 6 weeks from all double-blind placebo-controlled RCTs with fluoxetine and venlafaxine that were conducted by the sponsors. Statistically and clinically significant benefits of treatment were found. Based on relative change in slopes, remission rates, response rates, and NNTs, the treatment effect was largest for youths followed by adults and more limited for geriatric patients. Similar results were found for fluoxetine and venlafaxine.
While average differences at 6 weeks are relatively small, they translate into clinically significant differences in response and remission rates. In adults treated with fluoxetine, 55.1% of treated patients achieved response (50% reduction in severity) compared with only 33.7% of control patients; this is similar to previous causal inference (growth mixture modeling) findings for fluoxetine and imipramine.15 From a public health perspective, this is an enormous difference and indicates that for every 5 treated patients an additional patient treated with fluoxetine will respond. Similarly, remission rates were 45.8% for treated patients but only 30.2% for control patients. Even stronger results were observed for children. In youth studies, 29.8% of treated children responded, whereas only 5.7% of children receiving placebo responded. Similarly, remission rates were 46.6% for treated children but only 16.5% for control patients. These rates translate into an additional child treated with fluoxetine responding and remitting for every 4 children treated. The higher rates of remission suggest that the remission criterion (CDRS-R score = 28) should be reevaluated.
By contrast, we found statistically significant (for HAM-D scores but not remission and response rates) but much less clinically significant effects for geriatric patients. Response rates were 37.3% for treated geriatric patients vs 27.4% for geriatric patients receiving placebo, translating to 1 additional patient responding to fluoxetine for every 17 patients treated. Remission rates were 26.5% for treated geriatric patients vs 20.0% for geriatric patients receiving placebo, which translates into 1 additional patient remitting with fluoxetine for every 39 patients treated. The efficacy of antidepressant treatment in geriatric patients should be studied in greater detail based on these findings. There may be a biological explanation for the age effect on response rates because both neuroendocrine challenge studies and receptor imaging studies report poorer antidepressant responses in depressed patients with more pronounced serotonin abnormality.16,17 Serotonin function declines with age, potentially increasing the proportion of such patients in geriatric studies.
Venlafaxine produced results similar to those of fluoxetine, suggesting that these results are not specific to fluoxetine. Increased efficacy for the IR formulation compared with the ER formulation was observed and should be further studied.
Perhaps most importantly, these findings illustrate that relatively small overall mean differences can translate into relatively large patient-level differences in clinically interpretable and meaningful end points such as response and remission. Statistically, these small changes in the mean of the distribution can often translate into much larger effects in the tails of the distribution.
Most studies were designed for achieving regulatory approval and do not demonstrate the maximum effect that a drug can produce. Some studies were as short as 6 weeks, whereas the maximum effect during an acute treatment episode is likely 12 weeks or longer. Few well-controlled studies, other than the long-term maintenance study by Frank et al,18 have documented response rates for extended treatment with a single effective antidepressant. In that study, the remission rate was 82%, with 75% achieving remission by 140 days.17 For fluoxetine, 23% of patients who were unimproved at 8 weeks showed full remission at 12 weeks.19
The findings of this study shed light on meta-analytic results that related the average study-level initial severity to the magnitude of treatment response. When examined at the patient level, baseline severity did not moderate treatment response for any end point, age group, or drug. Overall response rates were lower for geriatric patients than adults but did not vary by baseline severity. For children, response rates were lower overall compared with adults; however, here there were substantial differences between low and high baseline severity groups for both treated and control patients (ie, not a treatment-related effect).
Results of this study raise serious questions regarding the results of meta-analyses that are now so prevalent in guiding medical decisions. In addition to the obvious issues related to publication bias,1 the use of average end points gleaned from studies with a variety of different approaches to handling missing data (eg, last observation carried forward or completer analyses) and the loss of intermediate longitudinal measurements and their associated contribution to the overall estimate of variability can yield biased results. Reliance on metaregression to examine relationships that exist at the person level but are analyzed at the study level can lead to erroneous conclusions that are not supported when all available person-level data are available. We note, however, that the approach to research synthesis taken in this article requires that all studies use a common end point. The use of different end points in different studies is exactly the type of problem for which meta-analysis was designed and for which it should be used. In these cases, however, one must take great care to use a well-chosen effect size (not a mean difference, for example) that is both statistically and clinically meaningful.
This study has several limitations. First, we considered only 2 antidepressant medications, and other antidepressants may produce different effects. Indeed, fluoxetine is the only antidepressant approved for the treatment of childhood depression and is the only antidepressant that we studied in children. Second, there were only 4 youth trials and we must therefore interpret the estimated efficacy observed in these trials with caution. However, the rather impressive effects on clinically interpretable outcomes such as response and remission indicate the clinical benefit children may receive with careful pharmacologic treatment. These findings should also favor reconsideration of the risk-benefit equation that led to the black box warning for suicidal thinking and antidepressants in children.20 Third, a similar note of caution is in order for the results for the 4 geriatric studies, where some statistically significant but more marginal clinically significant results were observed. Fourth, the reported findings are limited to the first 6 weeks of study. Results may differ for long-term outcomes and may be stronger as the placebo benefit possibly degrades over time.19 Fifth, it is possible that some selection bias remains even though our synthesis included all studies conducted by the sponsors and was not limited to the subset of studies that were in the published literature. Sixth, our study used industry-sponsored studies that were designed to demonstrate efficacy and may have enrolled patients who may not have been representative of the patients seeking treatment for depression. However, 2 of the 4 youth studies were academic studies (Treatment for Adolescents With Depression Study and study X065). Because the largest effect of treatment was seen for youths and these studies are a mix of industry and academic studies, it seems unlikely that reliance on industry-sponsored studies produced biased results. Seventh, most of the studies had placebo lead-in periods that are designed to eliminate early placebo responders. However, an analysis21 of 75 RCTs involving antidepressants and placebo from 1981 through 2000 found that the use of a placebo lead-in period did not relate to the response rate in the placebo group (P = .73). Like us, these investigators also found that baseline severity did not predict placebo response. We note, however, that while this analysis did not find any effect of a prospective lead-in period on placebo response rates and did not find a relationship to baseline severity, it is possible that the method of analysis (analyzing response rates as opposed to absolute magnitude of change) may have missed meaningful effects of the lead-in period.
To determine whether we included the majority of placebo-controlled depression studies of fluoxetine, we reviewed the published literature on placebo-controlled RCTs of fluoxetine in the acute treatment of MDD that met the following criteria: (1) not sponsored by a pharmaceutical company; (2) not associated with a specific medical illness (eg, following myocardial infarction, AIDS); (3) not associated with comorbid substance abuse (including alcohol); (4) not associated with a specific diagnosable comorbid psychiatric disorder; (5) used the HAM-D; and (6) had a minimum enrollment of 30 patients. Knowledge Finder (Aries System) was used to search the PubMed database from 1966 through October 31, 2010. The Boolean search option, with word variants, was used to search "placebo controlled trials of fluoxetine in major depression." The search returned 329 references. Titles and abstracts of these references were reviewed to find articles potentially meeting these criteria (n = 13) as well as articles that were reviews or meta-analyses (n = 7). The reference lists for the reviews and meta-analyses were inspected for additional articles potentially meeting these criteria (n = 1). Following these 2 manual reviews, reprints of candidate articles were obtained and reviewed for the 14 candidate articles. Two articles fulfilled the criteria.22,23 The first study22 was restricted exclusively to patients meeting the Columbia criteria for atypical depression (while meeting criteria for MDD). This study was partially funded by Eli Lilly and Co and their data were not available to us. The second study23 was a small study conducted in Brazil comparing St John's wort (n = 20) with fluoxetine (n = 20) and placebo (n = 26) and was partially funded by the company supplying the St John's wort. This literature search confirms that few if any academic studies of fluoxetine in the treatment of adult depression were conducted and that our data represent the majority of available published (12 studies) and unpublished (8 studies) RCTs.
In conclusion, a detailed research synthesis using patient-level longitudinal data from all available youth, adult, and geriatric placebo-controlled RCTs of fluoxetine conducted by the sponsor reveals consistent statistically significant benefits of treatment, the magnitude of which was greatest in youths and smallest in geriatric patients (where differences in remission and response rates did not reach statistical significance). Analyses of venlafaxine RCTs confirmed the results for the efficacy of antidepressant treatment in adults. Baseline severity did not moderate the effect of treatment. Similar reanalyses should be conducted with other newer antidepressant medications to confirm these findings. This study also highlights many of the limitations of meta-analysis that combine evidence from multiple RCTs (eg, metaregression of study-level characteristics that exhibit interindividual variability, inconsistent and potentially biased handling of missing data). It further highlights advantages of a more complete person-level analysis when such data are available and increases the need for caution regarding interpretation of meta-analytic results when person-level data are not available.
Correspondence: Robert D. Gibbons, PhD, Center for Health Statistics and Departments of Medicine, Health Studies, and Psychiatry, University of Chicago, 5841 S Maryland Ave, MC 2007, Office W260, Chicago, IL 60637 (email@example.com).
Submitted for Publication: July 15, 2011; final revision received November 28, 2011; accepted December 1, 2011.
Published Online: March 5, 2012. doi:10.1001/archgenpsychiatry.2011.2044
Author Contributions: Dr Gibbons had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Financial Disclosure: Dr Gibbons has served as an expert witness for the US Department of Justice, Wyeth, and Pfizer Pharmaceuticals in cases related to antidepressants and anticonvulsants and suicide. Dr Brown directed a suicide prevention program at the University of South Florida that received funding from JDS Pharmaceuticals. Dr Mann has received research support from GlaxoSmithKline and Novartis.
Funding/Support: This work was supported by grants MH062185 (Dr Mann), R56 MH078580 (Drs Gibbons and Brown), MH8012201 (Drs Gibbons and Brown), and MH040859 (Dr Brown) from the National Institute of Mental Health and grant 1U18HS016973 from the Agency for Healthcare Research and Quality (Dr Gibbons).
Additional Contributions: Data were supplied by the National Institute of Mental Health (Treatment for Adolescents With Depression Study), Wyeth, and Eli Lilly and Co.
Create a personal account or sign in to:


text:
UTHealth, Athersys preclinical research on stem cell therapy for stroke presented at AHA conference
Medical researchers from The University of Texas Health Science Center at Houston (UTHealth) presented new research results at the American Heart Association International Stroke Conference that demonstrated how MultiStem®, a novel stem cell therapy being developed by Athersys, Inc. provided multiple benefits when administered in preclinical models of ischemic stroke. The study, conducted by leading researchers from the Department of Neurology at the UTHealth Medical School working in collaboration with scientists at Athersys, illustrated the potential benefits of MultiStem therapy for treating stroke. Researchers observed that intravenous administration of MultiStem one day after a stroke reduced inflammatory damage in the brain and resulted in a significant improvement in motor skills. "We are seeing a paradigm shift in the way some types of stem cells may enhance recovery from stroke," said Sean I. Savitz, M.D., principal investigator and associate professor of neurology at UTHealth. "The stem cells may actually exert some of their effects on other organs such as the spleen. The spleen seems to play an important role in some neurological disorders by contributing, for example, to ongoing inflammation and brain injury after stroke. We're finding these stem cells are working on dampening inflammation involving the spleen."
According to the American Heart Association, approximately 800,000 individuals suffer a stroke each year in the United States, and an estimated 2 million individuals suffer a stroke each year in the U.S., Japan, and major European countries combined. Approximately 85% of strokes are ischemic, meaning they are caused by a blockage of blood flow in the brain, which occurs as a result of a clot or "thrombus". Currently there is only one FDA-approved drug therapy for the treatment of ischemic stroke, the thrombolytic tPA, which helps to dissolve the flow-impeding blood clot. However, tPA must be administered within several hours from when the stroke has occurred in order to be effective. Due to its limited window, only about 5% of all patients who could potentially benefit from therapy with tPA actually receive treatment. Given the lack of effective therapies, many patients who suffer a stroke require extensive physical therapy or experience significant or permanent disability, and as a result, must receive long-term institutional care or be cared for by a family member. As a consequence of an aging population, recent forecasts from the American Heart Association project that the prevalence of stroke will increase by 25% in the next 20 years, and the total estimated annual cost for treating and caring for stroke survivors will skyrocket from $64 billion in 2010 to $140 billion in 2030, representing a substantial increase in cost to the national healthcare system.
In the rat model of stroke used in the study, animals that received treatment with MultiStem showed statistically significant improvement in motor skills relative to animals that received placebo, and also showed reduced cell death, reduction of inflammatory cytokines and an increase in anti-inflammatory cytokines. Interestingly, researchers found that animals treated with placebo showed a reduction in spleen size and an increase in inflammatory cytokines in the blood, whereas animals that were treated with MultiStem showed normal spleen size and increased levels of anti-inflammatory cytokines in the blood. The spleen is believed to play a significant role in promoting and sustaining the inflammation that can result in substantial long-term damage following brain injury.
"Ischemic stroke represents an enormous clinical, economic and social burden that is expected to increase dramatically in the years ahead as a result of an aging population, and the corresponding increase in the number of individuals that are susceptible to all forms of cardiovascular disease," said Gil Van Bokkelen, Chairman and Chief Executive Officer of Athersys. "MultiStem appears to have profound effects in multiple neurological injury models, by reducing inflammation, protecting at-risk brain tissue, and promoting tissue repair. If we can develop new, more effective therapies that meaningfully extend the treatment window for stroke victims, we can improve clinical care, reduce long-term health care costs, and improve the quality of life for millions of people."
Source: University of Texas Health Science Center at Houston
Articles on the same topic
- UCLA Neurology plays key role in assessing stroke rehabilitationMon, 14 Feb 2011, 14:02:47 UTC
- Study looks at getting stroke patients back on their feetFri, 11 Feb 2011, 19:33:29 UTC
- Study yields promising results for patients with strokeFri, 11 Feb 2011, 17:06:55 UTC
- Robot therapy can improve arm, shoulder mobility after strokeThu, 10 Feb 2011, 18:35:58 UTC
Other sources
- Study yields promising results for patients with strokefrom Science DailyMon, 14 Feb 2011, 5:30:54 UTC
- Stroke rehab doesn't have to be high-tech to helpfrom PhysorgFri, 11 Feb 2011, 21:31:09 UTC
- Study looks at getting stroke patients back on their feetfrom Science BlogFri, 11 Feb 2011, 20:30:33 UTC
- Stroke rehab doesn't have to be high-tech to helpfrom AP HealthFri, 11 Feb 2011, 20:00:36 UTC
- Study looks at getting stroke patients back on their feetfrom PhysorgFri, 11 Feb 2011, 20:00:22 UTC
- Study yields promising results for patients with strokefrom PhysorgFri, 11 Feb 2011, 17:31:01 UTC
- Study yields promising results for patients with strokefrom Science BlogFri, 11 Feb 2011, 17:01:14 UTC
- Robot therapy can improve arm, shoulder mobility after strokefrom Science DailyFri, 11 Feb 2011, 2:30:35 UTC
- UTHealth, Athersys preclinical research on stem cell therapy for stroke presented at AHA conferencefrom PhysorgThu, 10 Feb 2011, 19:32:16 UTC
- Robot therapy can improve arm, shoulder mobility after strokefrom PhysorgThu, 10 Feb 2011, 18:31:04 UTC


text:
"Die Hard" director John McTiernan was sentenced Monday to a year in federal prison and fined $100,000 for lying to FBI agents and a federal judge in a wiretapping and racketeering case involving a former sleuth to the stars.
"The defendant doesn't think the law applies to him, and the court has no reason to believe he will not violate the law again when it suits him," U.S. District Judge Dale S. Fischer said before imposing the sentence.
McTiernan was indicted in April 2009 in U.S. District Court in downtown Los Angeles on two counts of making false statements to federal agents and one count of perjury.
The case dates to 2006, when McTiernan pleaded guilty to a charge of "knowingly lying" to FBI agents involved in the Anthony Pellicano case.
Shortly afterward, the filmmaker asked to back out of his plea, arguing that he had received poor legal advice and was jet-lagged and under the influence of alcohol when federal agents interviewed him.
Instead, Fischer sentenced him to four months in federal prison and fined him $100,000.
On April 17, 2009, McTiernan was indicted by a federal grand jury on the current charges, and pleaded guilty on July 12.
Along with the 12-month prison term and fine, Fischer ordered McTiernan to serve a three-year term of supervised release. The judge allowed the filmmaker to remain free on bond pending appeal.
"Regardless of a person's status, lying to law enforcement and to a federal court are serious crimes deserving of punishment," Assistant U.S. Attorneys Daniel A. Saunders and Kevin M. Lally said in a joint statement. "We believe that the sentence imposed today reflects this fact."
McTiernan, whose directing credits include "Predator," 'The Thomas Crown Affair" and "The Hunt for Red October," declined an opportunity to address the court.
Defense attorney Oliver Diaz said afterward that his client had been "forced to plead guilty to a crime most people don't even know is a crime."
McTiernan pleaded guilty "in order to take his case directly back to the Ninth Circuit where we firmly believe he will prevail," his lawyer said.
Diaz said the charge of lying to FBI agents stems from a telephone conversation his client had with federal agents in which the government "ignored several of its own internal policies," and did not read McTiernan his Miranda rights or tape-record the conversation.
"The agent did not tell Mr. McTiernan that he was the subject of an investigation for an event that had occurred six years earlier," Diaz said.
In his initial 2006 guilty plea, McTiernan admitted he hired Pellicano to illegally wiretap film producer Charles Roven after they worked on the 2002 film "Rollerball," and then lied to an FBI agent about the bugging.
Fischer said today that McTiernan's crimes "do not reflect a momentary lack of judgement or aberration."
Amid his legal problems, McTiernan directed a documentary that claims former Bush administration adviser Karl Rove pursued the Pellicano case as part of a conspiracy under Bush to prosecute Democrats.
Pellicano, now 66, was convicted of 78 felonies, including racketeering, conspiracy and wiretapping, at two separate trials in 2008. The former private eye to the stars is currently serving a 15-year sentence in federal prison.


text:
Classic French Pornstar – Brigitte Lahaie
"Introducing" one of my favorite classic pornstars of the 1970s, the very French and very very sexy Brigitte Lahaie. Gorgeous, with a natural Gallic charm and naturally amazing rack, beautiful eyes, long stunning legs, and a perfect all-natural hairy pussy framed by curvy thighs… yum.
Many thanks to Delta of Venus Vintage Erotica for tracking down and restoring this photo along with the others of Brigitte their classic smut archives.


text:
Preschool Development Planning--Community Feedback Survey
Floyd County Schools- All Seven Elementary Schools and Sixteen Classrooms Achieve a 5 STAR Quality Rating!
School Readiness in Kentucky
The Floyd County Schools Early Childhood Program is shaping the future by empowering children and families so that each child enters school ready to engage in and benefit from early learning experiences that best promote the child's success.
The future strength of the Commonwealth of Kentucky depends upon the healthy development of our youngest citizens. Our mission, therefore, is to build upon existing resources, foster public-private partnerships, ensure collaborative planning and implementation, and mobilize communities to: support and strengthen families; assure that all children grow and develop to their full potential; provide high quality, accessible, affordable early care and education options; and promote public awareness of the importance of the first years for the well-being of all Kentucky's citizens.
…is that all young children in Kentucky: are healthy and safe; possess the foundation that will enable them to have school and personal success; and live in strong families that are supported and strengthened within their communities.
The Floyd County Schools Early Childhood staff and programs are dedicated to our mission and vision. We understand fully the privilege and responsibility we have to every child entering our programs. Early Childhood staff members are dedicated and focused on providing students a great start to their school careers. They prepare students for transitioning into elementary school and build confidence and skills in each child for personal success and school readiness. Strong parent involvement and participation is encouraged, fostered, and appreciated. The benefits to both children and families are long lasting. The research clearly indicates that children attending Early Childhood programs have greater success in school. We are proud to make a difference in the lives of the children we serve and empower our students and their families to be informed, confident, and contributing citizens in shaping our future.
If you have a child turning three or four before October 1, we invite you to register for consideration to participate in the Early Childhood Program. The Floyd County Schools Early Childhood Program serves three and four year old children in Head Start and Preschool. Refer to other sections of this web page to learn more about the Early Childhood Program and the application process.
This year, the registration period will begin in April for new students for the next school year. Together, as partners, we collaborate with parents and other community agencies and organizations to continue to be a program of excellence for our youngest citizens. We are proud of our Early Childhood Program and invite you to join us as a participant, volunteer, or program supporter.


text:
We Recommend
FemGuard+Balance 120 capsules
Price: $50.75
Women's Twice Daily Essential
Price: $124.45
Due to its crystalline structure, absorption of DIM is minimal when given orally. For this reason, DIM-Evail™ has been manufactured utilizing the new Designs for Health Evail™ process, which is an all-natural process and formulation that improves the absorption of DIM. This process utilizes a proprietary blend of MCT oils, non-soy derived lecithin, and vitamin E without the use of potentially harmful surfactants.
The Designs for Health Evail™ Process delivers:
The Designs for Health Evail™ Process delivers:
- Increased absorption rates
- Reduced absorption times
- Greater effects with lower dosage
As a dietary supplement, take one softgel per day with a meal, or as directed by your health care practitioner.
Serving Size: 1 softgel
Servings Per Container: 120
Serving Size: 1 softgel
Servings Per Container: 120


text:
WoW Archivist explores the secrets of World of Warcraft's past. What did the game look like years ago? Who is etched into WoW's history? What secrets does the game still hold?
In many ways, The Burning Crusade was the birth of modern WoW. Most of TBC's innovations are still going strong in WoW today and have been ever since their introduction. Looking back, it's striking how many key features of WoW were absent in classic, only unveiled during the game's first expansion.
Even more striking, however, is how many of these innovations Warlords of Draenor seems poised to undo. Just as Garrosh will undo the transformation of Draenor into Outland, Warlords seeks to unravel most of what Blizzard innovated during TBC. The next expansion will take us through a portal into a very different WoW.
Archivist has now covered all the major patches of The Burning Crusade: patch 2.0.1, patch 2.0.3, patch 2.1, patch 2.2, patch 2.3, and patch 2.4. Now it's time to review the expansion as a whole -- and explore how Warlords will make most of TBC's innovations disappear into the nether.
Dawn of the quest hub
The idea seems so obvious it's hard to imagine that classic WoW actually didn't have quest hubs, at least not in the strict sense. WoW was the first MMO to promote the idea of leveling mainly through quests rather than grinding mobs. So Blizzard had no model to look at when they were designing the original quests.
In classic WoW, quests were put into the game wherever the developers thought they made sense, mostly from a lore perspective. Quests didn't necessarily guide you through a zone area by area. Quests were scattered, and their objectives were, too. They weren't breadcrumbs -- they were meant to be discovered. They didn't hold your hand -- they sent you on an adventure, like it or not.


text:
CHICAGO – It's coming! YippieFest 2020 – joining the virtual and online revolution during these particular times – is set for August 22nd and 23rd. Details to come on schedules and times, but the whole fest can be downloaded for FREE on those dates through TWITCH streaming service. Click here for more details. !—break—>
Jon Huertas
Interview: Director Kyle Ham on the Chicago Premiere of 'Reparation' on Sep. 10, 2016Submitted by PatrickMcD on September 9, 2016 - 4:22pm
CHICAGO – The premiere of a new director's work is cause for an event, and the new film "Reparation" will get its Chicago premiere on September 10th, 2016, at the suburban Wilmette Theatre (details below). "Reparations" is a war and military story, but mostly about the war at home after the service.
TV Review: Stana Katic, Nathan Fillion Continue to Carry 'Castle'Submitted by BrianTT on September 19, 2011 - 1:47pm
CHICAGO – The new season of ABC's hit "Castle" picks up right where the stunning cliffhanger of season three left off. Kate (Stana Katic) has been shot. Castle (Nathan Fillion) has confessed his love for her in the emotion of the moment. And we race with everyone to the hospital as they try to save Kate's life.
DVD Review: Second Season of ABC Hit 'Castle' With Nathan FillionSubmitted by BrianTT on September 27, 2010 - 1:37pm
CHICAGO – ABC's "Castle" has become one of the more reliable mystery shows on television; a wonderful piece of comfort food after a hard Monday at the office. With the amazing chemistry and perfect timing of stars Nathan Fillion and Stana Katic to drive it, the show went from barely-renewed to a program that feels like it will be on for years to come. Check out the second season, now on DVD, to see how a mystery series becomes a hit.
TV Review: 'Castle' Returns With Same Strengths, FlawsSubmitted by BrianTT on September 20, 2010 - 8:08am
CHICAGO – The best thing about the third-season premiere of the consistently-entertaining "Castle" may be that they've finally taken that stupid "Turner & Hooch" line out of the introduction to the hit mystery show. Other than that, the show pretty much picks up where it left off with two of the most charismatic stars on television often disguising the fact that the writing doesn't live up to their talents.
TV Review: 'Castle' Continues to Improve With Season-Two PremiereSubmitted by BrianTT on September 21, 2009 - 9:42am
CHICAGO – Nathan Fillion and Stana Katic bring their spectacular chemistry back for another season of the increasingly enjoyable "Castle," a mystery-of-the-week show distinguished by excellent writing and some of the best lead chemistry on television.
TV Review: Nathan Fillion, Stana Katic Have Perfect Chemistry on Promising 'Castle'Submitted by BrianTT on March 9, 2009 - 11:15am
Television Rating: 4.0/5.0
CHICAGO – Is it finally time for Nathan Fillion to become a star? One of the most charismatic TV actors of the last few years should have become a legend for his work on "Firefly," but that wasn't meant to be. Now he's back and just as good opposite Stana Katic on the very-promising "Castle," a mystery-of-the-week show distinguished by the excellent chemistry of its leads.
DVD Review: 'Generation Kill' Defines New Face of American WarSubmitted by BrianTT on December 17, 2008 - 3:26pm
CHICAGO – David Simon and Ed Burns, two of the television geniuses behind "The Wire", turned their eyes and ears from the gang-ridden streets of Baltimore to the bullet-strewn bodies of Iraq in the incredible seven-part HBO mini-series "Generation Kill", now available in a box set from HBO Home Video.


text:
Rifrange milioni di particelle luminose! Indossala e non passerai inosservataRead More
Per una sfavillante notte di capodanno
Paillettes, luccicanti ed eleganti, ti accendono di luce ..Read More
Arty crop top mania
You can find these exclusive single pieces of croptops on http://www.ebay.it/itm/vendo-crop-top-nuovo/162572346665?ssPageName=STRK%3AMEBIDX%3AIT&_trksid=p2060353.m1438.l2649Read More
https://it.shpock.com/i/WTheuuhPX0BxXi3s/ https://it.shpock.com/i/WTkKG0lJbykSOk2g/Read More
cola chiken
Ingredients: 1/2 litre cola (regular or diet) 1/4 cup ketchup 2 tablespoons of finely chopped onions 1/4 tablespoon oregano 1/4 garlic powder 2 bone in chiken tighs Pick a pot, and pour down cola, ketchup, onions, oregano e garlic powder. Bring all the ingredients to boil. Let them boil for a minute. Add the chiken. […]Read More
City of the day: Muskat
Capital of Oman, Muskat is one of the most amazing places of the world. in fact, though touristically under the radar, Muskat has nothing to envy to other places. Sprung up on the Arabian Sea, Muskat is surrounded by a magical desert whose fine sand can constitute isolated beaches– where eggs of seaturtles can be […]Read More
Persian Lamb
Ingredients: 1 teaspoon ground cinnamon 1 teaspoon ground nutmeg 1/2 teaspoon ground cardamom 1/2 teaspoon ground cumin 1 orange 1/2 cup chicken stock 1 lamb shank 1 cup of rice 1/2 sliced red onion 1 crushed garlic clove 30 g chopped pistachios 30 g dried cranberry parsley toasted almonds oil yoghurt (if you like) Preheat […]Read More
Night in… Anyone Movies?4
Dear Zindagi: With Alia Bhatt, Shah Rukh Khan, Aditya Roy Kapoor, Angad Bedi, Tahir Raj Bhasin. An inspiring cinematographer meets an unconventional thinker who revolutionizes her life, and helps her to find happiness. Paterson: With Adam Driver, Golshifteh Farahani, Kara Hayword, Sterling Jerins, Jared Gilman. This movie is about the life of a normal couple […]Read More
Thai Prowns
Ingredients: 200 g prowns 1 stick lemongrass 1 teaspoon of ginger powder 1/2 lime 1 red chili 1 coriander 1 leek garlic salt black pepper seed oil Remove the external leaves of the stick of lemongrass, and dice the white part. Remove the stalk of the red chili and cut it into half. Crumble […]Read More
Advanced toothpaste, Regenerate is an extraordinary product for your teeth. It reverses the process of erosion, restores the natural enamel, re-giving you the smile.Read More


text:
A company you've probably never heard of has been resurrected and it has designed a car that will almost certainly never get made. Meet the new ATS.
We last saw Automobili Turismo e Sport on our list of history's most obscure cars. Designed by a bunch of engineers who left Ferrari, their ATS 2500 GT was one of the first mid engined road cars. It was very pretty, but they wasted all their money trying to race in F1. The company went out of business and everybody forgot about it. They do turn up at rich people's car shows every so often.
The brand has been resurrected, just like Bizzarrini, De Tomaso, Marcos, and Melkus just to name a few. Just like all of those companies, nothing will probably ever get made.
We will likely see a few prototypes running around and perhaps a handful of production cars. At best there will be a limited production run of a dozen or so cars, like the Cizeta C16.
But who cares? Their proposed 2500GT is gorgeous, it's supposed to be fast, and it will somehow have a 500-horsepower Subaru boxer engine behind the driver, so let's all drool over it. They even want to make a bike-engined track car, which
has always failed as a business model sounds cool.
Suckers that we are, we hope ATS won't join our list of awesome failed supercar manufacturers.
Photo Credit: ATS


text:
Former air hostess Geetika Sharma's mother, who committed suicide by hanging herself inside her house here Friday evening, left another suicide note for her son, asking him to be "strong," police said.
Deputy Commissioner of Police P. Karunakaran told IANS that a note was found from the spot, written by Anuradha Sharma and addressed to her son.
"She said in the note that she was in depression because of the death of her daughter and she too was committing suicide. She asked her son to be strong," Karunakaran said.
Geetika's mother committed suicide Friday and blamed the same people that her daughter had named in the notes that she left before committing suicide. Geetika's mother said she was taking the extreme step because her family was being harassed.
Anuradha Sharma, 52, was found hanging in her bedroom here at her Ashok Vihar residence around 5.50 p.m. Friday. A suicide note she left named former Haryana minister Gopal Goyal Kanda and his employee Aruna Chaddha - the same duo that Geetika held responsible for her suicide.
Karunakar told IANS that Anuradha was in depression since the death of her daughter August last year. The family and relatives had been paying her much attention in the wake of Geetika's suicide.
"On the day of the suicide, her son Ankit had called his mother to have lunch with him at his office, a few kilometres from the house... she refused to step out and said she would eat at home," the police officer said.
"A relative, Jyoti, spotted Anuradha's body hanging from the ceiling fan in the same room on the first floor where Geetika had committed suicide. She called Ankit Sharma (her son) and informed him," said the officer.
Delhi Police told IANS that a case of abetment to suicide has been registered against Kanda and Aruna Chaddha at the Bharat Nagar police station.
"We are also taking help of call records of Anuradha Sharma to ascertain whether Kanda, Aruna Chadha or their aides were threatening or harassing her family," Karunakarn told IANS.
The postmortem of the victim will be conducted Saturday at Babu Jagjeevan Ram Memorial hospital at around 2 p.m, an official said.
Geetika, 23, a former air hostess in the defunct MDLR airlines belonging to Kanda, had committed suicide on the intervening night of Aug 4-5, 2012 by hanging herself from a ceiling fan at her house.
She had left two suicide notes naming Kanda and Chaddha for harassing her and driving her to suicide. Both Kanda, who is the prime accused in the case for abetting the suicide of Geetika, and Chaddha, are now in judicial custody, and have denied the allegations.


text:
When working on clients' financial solutions, we understand we are dealing with their lives and their future. This is why knowledge and expertise are critical. Our financial representatives receive rigorous training and regularly attend continuing education programs. They draw upon the extensive resources of the Northwestern Mutual to customize solutions that suit clients' individual personal or business needs by working closely with a team of specialists.
Our representatives use their knowledge to create a flexible yet tailored financial approach that can accommodate clients' changing situations. And, they rely on the expertise of our specialists to offer complementary financial solutions including life insurance, disability income insurance, education funding alternatives, retirement solutions, estate analysis, and business needs analysis.


text:
Tagged: Victor Martinez
Will Prince's Move to Tigers be as Good as Advertised?
The Tigers certainly seem in it to win it. Victor Martinez out for the season? No problem, let's spend $214 million on Prince Fielder to replace him.
With yesterday's signing, Detroit should unquestionably be the heavy favorites to win the A.L. Central. But we all know that the winners in the offseason aren't always the winners when all is said and done.
The combination of Fielder and Miguel Cabrera hitting back to back in scary. And add Justin Verlander heading up a solid pitching staff, it's pretty hard to think the Sox, Indians, Royals or Twins could outlast the rivals from Motown.
That said, stranger things have happened and it would be foolish to just give up and hand over the division title to Detroit. From a White Sox perspective, let's just hope Adam Dunn, Alex Rios and Gordon Beckham rebound and our newly-formed pitching staff delivers. If they do, the South Siders certainly could be as big a pleasant surprise as we were a disappointing one a year ago.
When I heard the Fielder announcement, all I could think of was that the Sox once had Frank Thomas and Albert Belle hitting back to back–a duo even more formidable than the Fielder/Cabrera duo. And the record shows that it didn't produce a championship team. In fact, the Sox finished around .500 in both seasons Thomas and Belle played together.
So, keep the faith.


text:
Snyder, Christian (1870-1948)
Christian Snyder: deacon in Mennonite churches in Roseland, Nebraska, Filer, Idaho, Duchess, Alberta, Creston, Montana, and Canby, Oregon, was born near Freeport, Illinois on 4 April 1870 and died at Canby, Oregon, 10 March 1948. He married Jessie May Easter on 24 December 1890. They were parents of three daughters. Jessie died 12 February 1893. Christian married Nancy Elizabeth Shupe on 9 January 1896. They were parents of two daughters and six sons. Christian's second wife died in 1930. After her death he lived at different times with his daughters.
Christian Snyder was baptized and received into the Roseland, Nebraska Mennonite church on 25 August 1892. Ten years later, on 25 September 1902, he was ordained to the office of deacon in the Roseland church. He served there until 1913 when the family moved to Filer, Idaho. In 1917 the family moved again, living and serving briefly in Duchess before another move in the fall of 1917, this time to Creston, Montana. The Snyders left Montana in 1921 or 1922. Chris, having been ordained a deacon for life, served in that capacity in the various churches of which he became a member as a result of his frequent moves.
Conference and Mission Board activities, first with the Kansas-Nebraska Conference and then with the Pacific Coast Conference, took up a good deal of Christian Snyder's time. He served as President of the Mission Board of the Pacific Coast Conference for twenty-three years and expressed great satisfaction that, throughout that time, he had a perfect record of attendance. He was also interested in singing, promoting singing classes and song programs in the church. He lived sacrificially, regarding the Scriptures as a complete guide to Christian life.
Mountain View Mennonite Church. A History of the Church at Creston, Montana. Kalispell, Montana: Mountain View Mennonite Church, 1992.
Regehr, T. D. Faith, Life and Witness in the Northwest, 1903-2003: Centennial History of the Northwest Mennonite Conference. Kitchener, ON: Pandora Press, 2003.
Obituary notice for Christian Snyder in the Gospel Herald.
|Ted D Regehr
|Date Published
|December 2003
Cite This Article
MLA style
Regehr, Ted D. "Snyder, Christian (1870-1948)." Global Anabaptist Mennonite Encyclopedia Online. December 2003. Web. 15 Aug 2020. https://gameo.org/index.php?title=Snyder,_Christian_(1870-1948)&oldid=143235.
APA style
Regehr, Ted D. (December 2003). Snyder, Christian (1870-1948). Global Anabaptist Mennonite Encyclopedia Online. Retrieved 15 August 2020, from https://gameo.org/index.php?title=Snyder,_Christian_(1870-1948)&oldid=143235.
©1996-2020 by the Global Anabaptist Mennonite Encyclopedia Online. All rights reserved.


text:
NRA chief says gun owners will 'stand and fight'
- LaPierre spoke to more than 600 wild turkey hunters%2C conservationists
- Says Obama%27s proposals are meant to %27dismantle%27 Second Amendment
- NRA leader repeats call for armed guards%2C police officers in every school
NASHVILLE, Tenn. -- The head of the National Rifle Association vowed to fight new gun legislation and renewed his call for armed guards in schools on Thursday, speaking before the National Wild Turkey Federation's annual convention in Nashville.
NRA CEO and Executive Vice President Wayne LaPierre heavily criticized President Obama's State of the Union address for not mentioning school safety.
LaPierre told the crowd of more than 600 wild turkey hunters and conservationists gathered at the Gaylord Opryland Hotel that Obama's proposals to ban military-style semiautomatic rifles and magazines that hold more than 10 bullets, and to require background checks for all gun sales, are efforts to "dismantle" the Second Amendment.
He said the president's initiatives were not about making schools safer.
And he said NRA members will fight those proposals.
"For our Second Amendment freedom, Mr. President, we will stand and fight throughout this country as Americans for our freedom, we promise you that," LaPierre said to applause. "Every single one of us from one end of the country to the other, we will stand and fight."
LaPierre also repeated the claim that pending legislation would lead to the registration of all guns. But that claim that has been widely criticized since the president has not proposed such a measure and federal laws prohibit background check information from being retained for more than 24 hours.
"It's gonna be our names, the names of good people, that will be put into this massive database, subject to federal legislation and subject to abuse of your privacy," LaPierre said.
The NRA's leader also renewed calls to put armed guards or police officers in every school, something that Obama also is proposing in the form of more funds for school resources officers.
National Wild Turkey Federation CEO George Thornton applauded LaPierre's speech, saying he worried that any new gun regulations would lead down the path of fewer gun rights.
"We're also very concerned about the movement in the United States to limit access to weapons," he said. Once you start to limit things, the limits begin to chip away."
He acknowledged that turkey hunters don't use military-style rifles. And he supports universal background checks. But instead of new laws, he said the federal government needs to do a better job of enforcing current laws.
"I support all the legislation that we have now," he said.
Mike Sentell, a Dyersburg, Tenn., hunter and state turkey federation board member, said the proposed legislation is "destroying our Second Amendment, one inch at a time."
"Semi-automatics are needed across the country for home protection or sports," he said. "If they're successful at doing that, then they can take the rest of them away."


text:
Wheat growers have a new Bayer CropScience herbicide with a new active ingredient. Huskie Complete received approval from EPA for application to cereals, including spring wheat, winter wheat and durum. The new herbicide will control grass weeds including those that are ACC-ase resistant, such as wild oats, barnyardgrass and green and yellow foxtail. Huskie also will handle more than 50 broadleaf weeds, including ALS-resistant biotypes, including common lambsquarters, Russian thistle, and prickly lettuce.
"Most wheat fields contain a mixture of grass and broadleaf weeds, requiring the use of multiple products in one application," reported John McGregor, cereals herbicide product manager, Bayer CropScience. "In one product, and one application, Huskie Complete provides cross-spectrum weed control of the most important grass and broadleaf weeds in wheat.
For more information about Huskie Complete, visit www.BayerCropScience.us.


text:
Skip to main content
Loyola University Maryland
Report Bias
Recognize & Reject Bias
Report Bias
Witness Considerations
Target Considerations
Diversity Advisory Board
Report Bias Form
Witness Considerations
Witness Considerations
If you have been a witness of bias related behaviors, please consider the following:
If emergency situation (need medical attention or feel unsafe) call Campus Police at 410-617-5911 or 911 immediately.
Preserve the evidence.
Written slur, graffiti, and/or text message – Do not erase the text.
E-mail, Facebook message, etc. – Print as soon as possible.
Voice mail message – Save it. Do not erase the recorded message.
Take a picture or video record the evidence (graffiti, physical injuries, license plate, or anything else relevant)
Verbal incident/altercation – Immediately write down everything that was said.
Witnesses – Gather witness information and encourage them to submit a report/document what they observed.
Report the incident. There are several avenues for reporting bias related behaviors.
online form
. Documents, pictures, etc. can be uploaded on the form.
Contact the Dean of Students Office 410-617-5171 or stop by Jenkins Hall 105.
Contact an RA or member of Student Life staff. Student Life staff members are required to report bias behaviors to their immediate supervisor and complete the online bias related behaviors report form. This form is sent directly to the Associate Dean of Students.
Contact Campus Police 410-617-5911.
You do not have to determine whether or not the offensive conduct constitutes as bias related behaviors. Report the behaviors and the Dean of Students Office will begin the investigation process to determine the best way to address the incident. The incident will be handled in a confidential manner, except in cases where the University is required by law to notify the community. In cases of notification, the person reporting the behaviors/targeted person will be consulted to determine the appropriate communication to the community.
It is best to report behaviors as soon as possible to facilitate the investigation.
Seek out support. For support in coping with and managing these situations, please contact one of the following departments:
Dean of Students Office: 410-617-5171
Counseling Center: 410-617-2273
ALANA Services: 410-617-2310
Campus Ministry: 410-617-2768
Center for Community Service and Justice: 410-617-2380
Disability Support Services: 410-617-2750
Student Life: 410-617-5081
Women's Center: 410-617-5844
Report Bias
Witness Considerations
Target Considerations


text:
Venkatapathi Puvvada
Chief Technology Officer, Unisys
5 IT priorities for 2009
5 technology waves to ride in 2009
1. IT infrastructure consolidation: Cloud computing, virtualization of IT resources, green computing
2. Transparency of government data and technologies that enable it, such as service-oriented architecture, Web 2.0, etc.
This would include new vehicles for transparency and accountability as well as refocused attention on citizen participation in government (along lines of IT as a direct interaction mechanism for the just-concluded presidential campaign). This presumably would include 21st century collaboration technologies previously not adopted widely in government but popular for professional and social networking.
3. Improved communication/collaboration with citizens/interest groups, and technologies that enable this, such as social networking, YouTube-style video publishing, blogs, wikis, etc.
End-user services enablement and collaboration includes integration of tools and technology to empower workers, such as e-mail, v-mail, knowledge sharing portals, productivity tools, virtualized desktop, mobile device applications, anytime/anywhere network access, etc.
About the Author
Connect with the GCN staff on Twitter @GCNtech.
E-Mail this page
Printable Format
Advanced Search
Sign up for our newsletter.
I agree to this site's Privacy Policy.